Clinical trials: Oropharyngeal
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Squamous Cell Carcinoma of the Oropharynx
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.
- Trial name
- NCT04398524
- Testing
- ISA101b
- Where
- 41 sites in United States, Belgium and 7 more
- Volunteers
- 65 people
- Sponsor
- ISA Pharmaceuticals
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
The purpose of this study is to determine the safety, tolerability, and the highest dose of GC4419 that can be given to patients with squamous cell cancer of the head and neck who are receiving standard radiation therapy and…
- Trial name
- NCT01921426
- Testing
- GC4419
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Galera Therapeutics, Inc.
Cervical Cancer, Head and Neck Squamous Cell Carcinoma
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 TCR-T cell for HPV18 positive advanced solid tumor.
- Conditions
- Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Cancer, Vagina Tumor
- Trial name
- NCT05787535
- Testing
- Fludarabine + Cyclophosphamide, HRYZ-T101 TCR-T Cell
- Where
- China
- Volunteers
- 17 people
- Sponsor
- HRYZ Biotech Co.
Oropharyngeal Candidiasis
A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis.
The objectives of this study are to compare the efficacy and safety of Clotrimazole troche/ lozenges USP, 10 mg (Unique Pharmaceutical Laboratories, India) vs.
- Trial name
- TPC (NCT02635438)
- Testing
- Unique Pharmaceutical Laboratories, India, Roxane Laboratories Inc., USA
- Where
- 26 sites in India
- Volunteers
- 360 people
- Sponsor
- Thinq Pharma-CRO Pte. Ltd.
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma, Unknown Primary
Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery
This is a single-arm, single site, multi-surgeon prospective feasibility study for transoral robot assisted surgery (TORS) with the Versius Surgical System.
- Trial name
- NCT06112535
- Testing
- Versius Surgical System
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- CMR Surgical Ltd
Head and Neck Cancer
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00022217
- Testing
- carboplatin, cisplatin-e therapeutic implant, paclitaxel
- Where
- 4 sites in United States
- Sponsor
- Matrix Pharmaceutical
Oropharyngeal Carcinoma (OPC)
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer.
- Trial name
- TEMPO-1 (NCT07768189)
- Testing
- CRB-701, capcitabine, Cetuximab (EGFR inhibitor)
- Where
- 111 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Stroke, Parkinson Disease
Videofluoroscopic Swallowing Study (VFSS)
The study procedure of simultaneous VFSS and DDS measurement will be completed in one day and the subject will be followed within 2 business days after the study procedure to monitor for adverse events.
- Conditions
- Stroke, Parkinson Disease, Multiple Sclerosis, Oropharyngeal Dysphagia
- Trial name
- PORSCHE (NCT03387267)
- Testing
- Dysphagia Detection System
- Where
- 13 sites in United States, Finland
- Volunteers
- 452 people
- Sponsor
- Société des Produits Nestlé (SPN)
Pulmonary Disease, Chronic Obstructive
Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study to compare the lung and oropharyngeal deposition of Berodual® (fenoterol hydrobromide 50μg + ipratropium bromide 20μg /1x puff) delivered via the Respimat® inhaler and the same dose of Berodual® delivered via an…
- Trial name
- NCT02176200
- Testing
- Berodual® Respimat®, low inspiratory flow rate, Berodual® Respimat®, medium inspiratory flow rate, Berodual® Respimat®, high inspiratory flow rate
- Volunteers
- 3 people
- Sponsor
- Boehringer Ingelheim
Allergy
Ectoin Lozenges (EHT02) in the Treatment of Oropharyngeal Allergic Symptoms
The goal of this multicentric, prospective, randomised, controlled study (§23b German Act on Medical Devices (MPG)) is to investigate the efficacy of Ectoin Lozenges (EHT02) in treatment and prevention of oropharyngeal allergic…
- Trial name
- NCT03975257
- Testing
- Medical Device: Ectoin Lozenge
- Where
- 8 sites in Germany
- Volunteers
- 90 people
- Sponsor
- Bitop AG
Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
This is a multi-center, open-label, phase 1 dose escalation and expansion study evaluating the safety, anti-tumor effect, and immunogenicity of CUE-101 as monotherapy treatment in second line or CUE-101 Combination Therapy with…
- Conditions
- Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
- Trial name
- NCT03978689
- Testing
- CUE-101, KEYTRUDA®, Pembrolizumab
- Where
- 17 sites in United States
- Volunteers
- 80 people
- Sponsor
- Cue Biopharma
Head and Neck Cancer
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
The purpose of this study is to demonstrate the superior efficacy of Xevinapant (Debio 1143) versus placebo when added to radiotherapy in the treatment of high-risk participants with resected locally advanced squamous cell…
- Trial name
- NCT05386550
- Testing
- Xevinapant, IMRT
- Where
- 206 sites in United States, Argentina and 24 more
- Volunteers
- 166 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Oropharyngeal Cancer
Prospective, Multicenter da Vinci® SP™ Surgical System TORS Study
A prospective, multicenter investigation of the da Vinci® SP™ Surgical System in Transoral Robotic Surgery (TORS) procedures for malignant oropharyngeal tumors.
- Trial name
- NCT03049280
- Testing
- Transoral robotic surgery
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Intuitive Surgical
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Oral Mucositis
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers.
- Trial name
- KEVLARx (NCT05966194)
- Testing
- RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2
- Where
- 14 sites in United States
- Volunteers
- 216 people
- Sponsor
- EpicentRx, Inc.
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Head and Neck Cancer
Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003328
- Testing
- porfiromycin, radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Dysphagia
Efficacy of Natural Ingredient to Improve the Swallowing Response of Patients With Oropharyngeal Dysphagia
Assessment of the improvement of the safety of the swallowing function under 3 natural ingredients known to be agonist of sensory receptors.
- Trial name
- NCT02422576
- Testing
- cinnamon extract, lemon extract, lemon extract plus eucalyptus extract
- Where
- Spain
- Volunteers
- 104 people
- Sponsor
- Société des Produits Nestlé (SPN)